



Register of ASX Listing Rule Waivers

16 to 30 September 2026

The purpose of this register is to record when ASX has exercised its discretion and granted a waiver from the ASX Listing rules. Waivers are published bi-monthly and include information such as:

- Organisation**
- Rule Number**
- Decision Details**
- Basis for Decision**

For all product enquiries, please contact:

- Customer Service Centre on 131 279

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	2.1 Condition 3
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000524
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 2.1 condition 3 on condition that ASX is satisfied with the settlement arrangements that exist in relation to the notes quoted on ASX. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 2.1 condition 3 requires the securities or the CHESS Depositary Interests of an entity seeking admission to be approved under the operating rules of an approved clearing and settlement facility. This supports orderly settlement of securities quoted on the ASX market. Present Application The securities being quoted are wholesale debt securities. Trading in the securities is to be settled outside of CHESS via Austraclear. It is considered appropriate to grant a waiver on the condition that ASX is satisfied with the settlement arrangements that exist in relation to the debt securities to be quoted on ASX.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	8.10
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000526
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 8.10 to allow the Entity to refuse to register transfers of debt securities from the date which is 5 Business Days before an interest payment date or the maturity date of the debt securities, on condition that ASX is satisfied with the settlement arrangements that exist in relation to the notes to be quoted on ASX. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 8.10 requires an entity not to interfere with registration of a transfer document relating to quoted securities, subject to a number of exceptions set out in that rule. This supports the principle that quoted securities should be freely transferable. The rule also inhibits the ability of an issuer to cause disruption to the settlement cycle. Present Application The securities being quoted are wholesale debt securities. Trading in the securities is to be settled outside of CHESS via Austraclear. The Entity may refuse to register transfers from the date which is 5 Business Days before an interest payment date or the maturity date. This is a common arrangement for these types of securities and it is appropriate to grant a waiver in the

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

	circumstances.
--	----------------

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	1.8 Condition 11
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000523
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 1.8 condition 11 on condition that ASX is satisfied with the settlement arrangements that exist in relation to the debt securities to be quoted on ASX. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 1.8 condition 11 requires that an entity seeking admission as an ASX Debt Listing must be approved as an issuer of quoted securities or as a foreign issuer of CHESS Depositary Interests under the operating rules of an approved clearing and settlement facility. This supports orderly settlement of securities quoted on the ASX market. Present Application The securities being quoted are wholesale debt securities. Trading in the securities is to be settled outside of CHESS via Austraclear. It is considered appropriate to grant a waiver on the condition that ASX is satisfied with the settlement arrangements that exist in relation to the debt securities to be quoted on ASX.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	8.2
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000525
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 8.2 to the extent necessary for the Entity not to provide an issuer sponsored subregister for as long as the Entity has the benefit of a Listing Rule 2.1 condition 3 waiver. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 8.2 requires an entity to provide an issuer sponsored subregister for securities except where Listing Rule 8.2.1 allows for a certificated subregister. These arrangements support orderly settlement of securities quoted on the ASX market. Present Application This is a companion waiver to a waiver from Listing Rule 2.1 condition 3 granted to the Entity.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	8.21
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000527
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 8.21 to the extent necessary to permit the Entity to not do the following: 1.1 in respect of transactions settled outside CHESSE, mark transfer forms as required by Appendix 8A; or 1.2 in respect of transactions settled in Austraclear, send confirmation of a change of address to a security holder at the holder's old address. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 8.21 requires an entity to comply with the time limits set out in Appendix 8A. This supports the ASX Settlement Operating Rules and maintains an orderly market. Present Application The securities being quoted are wholesale debt securities. The likely holders of the debt securities are institutional investors. The waiver is granted to the extent that transactions are settled outside CHESSE.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	1.8 Condition 8 (b)
Date	16/09/2026
ASX Code	LR8
Listed Company	LA TROBE FINANCIAL CAPITAL MARKETS TRUST 2026-1
Waiver Number	WRR-0000522
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants La Trobe Financial Capital Markets Trust 2026-1 ('Entity') a waiver from Listing Rule 1.8 condition 8(b) to the extent necessary to permit the Entity to be a special purpose trust constituted solely for the purpose of conducting a securitisation transaction in relation to wholesale debt securities, one or more classes of which will be quoted on ASX. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotations disclosure.
Basis For Decision	Underlying Policy Listing Rule 1.8 condition 8(b) requires that an entity seeking admission as an ASX Debt Listing that is a trust must be a special purpose trust constituted solely for the purpose of issuing the class or classes of debt securities to be quoted on ASX. This is an investor protection mechanism which reduces the number of potential claimants on the assets of the trust, primarily preserving them for the benefit of holders of the quoted debt securities. Present Application The Entity is a special purpose trust constituted for the purpose of conducting a securitisation transaction under which the Entity acquired the securitised assets using funds raised by the Entity by issuing multiple classes of debt securities. The business of the trust is limited by

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

	the trust deed and related documentation for the securitisation transaction. The securities being quoted are wholesale debt securities and their terms of issue and ranking relative to other classes of securities (including classes not being quoted) were disclosed in an Information Memorandum. ASX considers that there are sufficient safeguards in place for the holders of the wholesale debt securities.
--	--

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	7.1
Date	17/09/2026
ASX Code	TBN
Listed Company	TAMBORAN RESOURCES CORPORATION
Waiver Number	WRR-0000531
Decision	1. Subject to paragraphs 2 and 3 and based solely on the information provided, ASX Limited ('ASX') grants Tamboran Resources Corporation (the 'Company') a waiver from Listing Rule 7.1 to the extent necessary to permit the Company to issue securities without security holder approval under Listing Rule 7.1, subject to the following conditions. 1.1 The Company remains subject to, and complies with, the New York Stock Exchange ('NYSE') Rules and the relevant U.S. Federal and State securities law applicable to Delaware incorporated companies with respect to the issuance of securities. 1.2 The Company obtains security holder approval for the implementation of the waiver by way of an ordinary resolution. 1.3 The waiver is granted for a fixed period of one year commencing on the date security holders approval is obtained, subject to paragraph 2. 1.4 The Company includes a statement in or with the full year accounts that are given to ASX for release to the market during the period of the waiver that summarises the waiver and confirms that the Company remains subject to, and continues to comply with, the requirements of the NYSE Rules and the relevant U.S. Federal and State securities laws for Delaware incorporated companies with respect to the new issue of securities. Prior to publishing this statement, the Company must confirm with ASX that there has been no change to ASX's policy settings in relation to security holder approval requirements. 1.5 If the Company becomes aware of any change to the application of the NYSE Rules and the relevant U.S. Federal and State securities laws for Delaware incorporated companies with respect to the issue of new

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	securities, or that the Company is no longer in compliance with the requirements of NYSE Rules or the relevant U.S. Federal and State securities laws for Delaware incorporated companies with respect to the issue of new securities, it must immediately advise ASX. 2. Without limiting ASX's right to vary or revoke its decision pursuant to Listing Rule 18.3, ASX reserves the right to revoke the waiver in paragraph 1 if: 2.1 the Company fails to comply with any of the conditions in paragraph 1; 2.2 there are changes to the NYSE Rules in respect of the issue of new securities; or 2.3 there are changes to ASX's policy settings in relation to security holder approval requirements arising from the current review of those settings or any subsequent review. 3. This waiver is granted on the condition that the Company releases an announcement to the market that discloses the nature and effect of the waiver and the Company's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Company that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.
Basis For Decision	Underlying Policy Listing Rule 7.1 requires an entity to adhere to an aggregate limit on the number of equity securities it can issue, or agree to issue, over any 12-month period without obtaining prior security holder approval. Subject to a number of exceptions in Listing Rule 7.2, the limit is approximately 15% of its fully paid ordinary issued capital. This seeks to balance the interests of an entity in being able to raise capital flexibly and the interests of its security holders in not being unfairly diluted. Present Application Tamboran Resources Limited, an Australian incorporated entity, was admitted to the Official List of ASX on 2 July 2021. The Company is incorporated under the laws of Delaware in the United States and was admitted to the Official List of ASX on 8 December 2023 following a 'top-

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	hat' scheme of arrangement with Tamboran Resources Limited. The Company subsequently listed on the NYSE on 28 June 2024 following re-domiciling to the United States. Guidance Note 4 – Foreign Entities Listing on ASX states ASX may, in very limited situations, recognise compliance by a foreign entity which has its primary listing on an overseas exchange with a particular obligation imposed by its home exchange as constituting, in principle, sufficient reason to justify the granting of a waiver from a comparable, but inconsistent, obligation under the ASX Listing Rules. ASX considers that the NYSE Rules and relevant U.S. Federal and State securities laws applicable to Delaware incorporated companies provide an acceptable alternative regime for the issue of securities. Having considered the factors outlined in section 3.4 of ASX Guidance Note 4 – Foreign Entities Listing on ASX, ASX considers, on balance, that it is appropriate to grant the relief on the condition the Company obtains security holder approval by ordinary resolution to implement the waiver. Security holder approval gives the Company's security holders an opportunity to consider and vote on a proposal that would result in it being subject to a different regulatory framework for the issue of securities than would otherwise apply under Listing Rule 7.1. The waiver is granted for a fixed period of one year, which provides an opportunity to review the continued appropriateness of the waiver on a regular basis. The waiver may be revoked if it becomes inconsistent with ASX's policy settings in relation to security holder approval requirements, which are currently under review.
--	--

Rule Number	1.1 Condition 12
Date	18/09/2026
ASX Code	INN
Listed Company	INNOVAERO TECHNOLOGIES LIMITED
Waiver Number	WRR-0000528
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Innovaero Technologies Limited (the 'Entity') a waiver from Listing Rule 1.1 condition 12 to have on issue 1,000,000 performance rights ('Performance Rights') with an exercise price of less than \$0.20, on condition that the full terms and conditions of the Performance Rights are clearly disclosed in the Entity's initial public offering prospectus. 2. The waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotation disclosure.
Basis For Decision	Underlying Policy Listing Rule 1.1 Condition 12 requires that if an entity seeking admission has options on issue (including options in the form of performance rights), the exercise price must be at least 20 cents in cash. The options the entity has on issue at admission should not undermine Listing Rule 2.1 Condition 2, which requires the issue price or sale price of all the securities for which a listing applicant is seeking quotation (except options) to be at least 20 cents in cash. These requirements together help ensure that the entity's ordinary securities have a minimum value suitable for an entity seeking admission. Present Application ASX has confirmed that it does not object to the terms of the Performance Rights for the purposes of Listing Rule 6.1. This waiver is a companion to that no objection.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	1.1 Condition 12
Date	18/09/2026
ASX Code	INN
Listed Company	INNOVAERO TECHNOLOGIES LIMITED
Waiver Number	WRR-0000529
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Innovaero Technologies Limited (the 'Entity') a waiver from Listing Rule 1.1 condition 12 to have on issue 3,816,794 options with an exercise price of less than AUD\$0.20 ('Options') on the condition that the full terms and conditions of the Options are clearly disclosed in the prospectus document. 2. This waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotations disclosure.
Basis For Decision	Underlying Policy Listing Rule 1.1 Condition 12 requires that if an entity seeking admission has options on issue (including options in the form of performance rights), the exercise price must be at least 20 cents in cash. The options the entity has on issue at admission should not undermine Listing Rule 2.1 Condition 2, which requires the issue price or sale price of all the securities for which a listing applicant is seeking quotation (except options) to be at least 20 cents in cash. These requirements together help ensure that the entity's ordinary securities have a minimum value suitable for an entity seeking admission. Present Application The Options do not represent a significant proportion of the Entity's undiluted issued capital. The facts of this matter lend support to grant the waiver

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	on the basis that the 20 cent rule will not be undermined for the following reasons: - The Options on issue were issued to one employee for employee services. - The Options do not undermine the integrity of the A\$0.20 rule having regard to the number on issue and the exercise price of the securities. It is proposed to grant the waiver to Listing Rule 1.1 condition 12.
--	--

Rule Number	1.1 Condition 12
Date	18/09/2026
ASX Code	PRB
Listed Company	PARBO RESOURCES LIMITED
Waiver Number	WRR-0000530
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Parbo Resources Limited (the 'Entity') a waiver from Listing Rule 1.1 Condition 12 to the extent necessary to permit the Entity to have on issue 6,350,850 performance rights ('Performance Rights') with an exercise price of less than \$0.20, on condition that the full terms and conditions of the Performance Rights are clearly disclosed in the Entity's initial public offering prospectus. 2. The waiver is granted on the condition that the Entity discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver as pre-quotations disclosure.
Basis For Decision	Underlying Policy Listing Rule 1.1 Condition 12 requires that if an entity seeking admission has options on issue (including options in the form of performance rights), the exercise price must be at least 20 cents in cash. The options the entity has on issue at admission should not undermine Listing Rule 2.1 Condition 2, which requires the issue price or sale price of all the securities for which a listing applicant is seeking quotation (except options) to be at least 20 cents in cash. These requirements together help ensure that the entity's ordinary securities have a minimum value suitable for an entity seeking admission. Present Application ASX has confirmed that it does not object to the terms of the Performance Rights for the purposes of Listing Rule 6.1. This waiver is a companion to that no objection.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	10.1
Date	21/09/2026
ASX Code	DXB
Listed Company	DIMERIX LIMITED
Waiver Number	WRR-0000534
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Dimerix Limited (the 'Entity') a waiver from Listing Rule 10.1 to the extent necessary to permit the Entity to grant a security interest over the assets of the Entity and its wholly owned subsidiary Dimerix Biosciences Pty Ltd (the 'Security Interest') to Skiptan Pty Ltd and Skiptan Pty Ltd as trustee for the P&M Meurs Family Trust (the 'Skiptan Entities') (the 'Related Party Lender') to secure the Entity's obligation in respect of principal drawn down and accrued interest under a loan facility to be provided by the Related Party Lender ('Loan Facility'), without obtaining shareholder approval, on the following conditions: 1.1 the Entity releases an announcement to the market that provides: 1.1.1 the material terms of the Loan Facility, the Security Interest, and of this waiver from Listing Rule 10.1; and 1.1.2 a description of the reasons why the Entity has chosen to obtain the Loan Facility from the Related Party Lender rather than a lender that is not a Listing Rule 10.1 party and the steps the board has taken to satisfy itself that the transaction is being entered into on arm's length terms and is fair and reasonable from the perspective of the holders of the Entity's ordinary securities; 1.2 the Security Interest documents expressly provide that: 1.2.1 the Security Interest is limited to the funds due under the Loan Facility; 1.2.2 the Security Interest will be discharged when the funds due under the Loan Facility have been paid in full; 1.2.3 in the event the Security Interest is enforced the assets can only be disposed of to the Related Party

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	Lender or associates of the Related Party Lender, if the disposal is first approved by the Entity's security holders under Listing Rule 10.1; and 1.2.4 otherwise, if the Related Party Lender exercises, or appoints a receiver, receiver and manager or analogous person to exercise, any power of sale under the Security Interest, the assets must be sold to an unrelated third party on arm's length commercial terms and the net proceeds of sale distributed to the Related Party Lender in accordance with their legal entitlements; 1.3 any variation to the terms of the Loan Facility or Security Interest which: 1.3.1 advantages the Related Party Lender in a material respect; 1.3.2 disadvantages the Entity in a material respect; or 1.3.3 is inconsistent with the terms of the waiver, must be subject to security holder approval under Listing Rule 10.1; and 1.4 for each year while they remain on foot, a summary of the material terms of the Loan Facility and the Security Interest is included in the related party disclosures in the Entity's audited annual accounts. 2. This waiver is granted on the condition that the Entity releases an announcement to the market that discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Entity that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.
--	---

Basis For Decision	Underlying Policy Listing Rule 10.1 requires an entity to obtain the approval of security holders for an acquisition or disposal of a substantial asset from or to a person in a position to exercise influence over the entity. This protects security holders from a value-shifting transaction between an entity and a person in a position to exercise influence over the entity without the disinterested security holders having approved that transaction with the benefit of full information. This supplements the related party provisions of the Corporations Act (or, in the case of a foreign entity, the related party provisions of the law of their home jurisdiction). Present Application The Entity is granted a waiver from Listing Rule 10.1 to enable it to grant the Security Interest in favour of the Related Party Lender, subject to a number of conditions, including that the Security Interest documents provide that in the event the Security Interest is exercised, neither the Related Party Lender nor any of its associates are entitled to acquire the assets without the Entity first complying with any applicable Listing Rules, including Listing Rule 10.1. This condition provides a sufficient safeguard against value-shifting to the Listing Rule 10.1 parties.
---------------------------	---

Rule Number	7.3.4
Date	21/09/2026
ASX Code	TLX
Listed Company	TELIX PHARMACEUTICALS LIMITED
Waiver Number	WRR-0000532
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Telix Pharmaceuticals Limited (the 'Entity'), a waiver from Listing Rule 7.3.4 in relation to its acquisition of ITM Isotope Technologies Munich SE ('ITM') (the 'Transaction'), to the extent necessary to permit the Entity in its notice of meeting ('Notice') seeking shareholder approval for the issue to the vendors of ITM of up to US\$1.65 billion worth of fully paid ordinary shares in the Entity as partial consideration for the Transaction ('Consideration Shares'), upon certain regulatory conditions being achieved or waived in relation to the Transaction including clearance or non-objection from the German Federal Ministry for Economic Affairs and Energy and clearance or non-objection by Innovation, Science and Economic Development Canada ('Conditions'), as well as the achievement of conditions related to FDA development targets of ITM's product ITM-11, not to state that the Consideration Shares will be issued within three months from the extraordinary general meeting ('EGM'). The Entity is entitled to hold back consideration otherwise due to be paid at the completion of the Transaction as Consideration Shares to take account of final adjustments to the consideration ('Adjustment Holdback') and in relation to indemnity arrangements ('Indemnity Holdback'). The waiver is granted on the following conditions: 1.1 the Consideration Shares, other than any Consideration Shares issued as a consequence of the release of the Adjustment Holdback or the Indemnity Holdback, are to be issued upon achievement or waiver of the applicable Conditions, and in any event, no later than 12 months from the receipt of shareholder approval for the issue of the Consideration Shares;

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	1.2 any Consideration Shares issued as a consequence of the release of the Adjustment Holdback are issued no later than 6 months from the completion of the Transaction; 1.3 any Consideration Shares issued as a consequence of the release of the Indemnity Holdback are issued no later than 18 months from the completion of the Transaction; 1.4 the material terms of the Consideration Shares must not be varied and are fully and clearly set out in the Entity's Notice seeking shareholder approval in respect of the issue of the Consideration Shares, including the relevant conditions for the issue of the Consideration Shares; 1.5 details regarding the potential dilutive effect of the Consideration Shares on the Entity's capital structure is included in the Notice to ASX's satisfaction; 1.6 the terms of the waiver are clearly disclosed in the Notice to ASX's satisfaction; 1.7 if any of the Conditions are achieved or waived, the achievement or waiver of that condition and the basis on which the Entity's directors determined that the condition has been achieved or waived is announced to the market, along with the number of Consideration Shares issued; 1.8 for any annual reporting period during which any Consideration Shares have been issued or any of them remain to be issued, the Entity's annual report sets out the number of Consideration Shares issued in that annual reporting period, the number of Consideration Shares that remain to be issued and the basis on which the Consideration Shares may be issued; and 1.9 the Entity releases an announcement to the market that discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Entity that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.
--	--

Basis For Decision	Underlying Policy Listing Rule 7.3.4 requires a notice of meeting with a resolution to approve an issue or agreement to issue equity securities under Listing Rule 7.1 to include the date or dates on or by which the entity will issue the securities, which must be no later than the applicable period referred to in Listing Rule 7.3.4. This strikes a balance between giving entities the time practically necessary to complete an issue of equity securities, and ensuring that the securities are issued within a reasonable time frame after security holder approval so that the approval is not rendered stale by subsequent events. Present Application Subject to shareholder approval, the Entity is proposing to issue up to US\$1.65 billion worth of fully paid ordinary shares in the Entity as partial consideration for the Transaction upon certain regulatory conditions being achieved or waived including clearance or non-objection from the German Federal Ministry for Economic Affairs and Energy and clearance or non-objection by Innovation, Science and Economic Development Canada to the Transaction. In addition to these regulatory approvals, commercial conditions relating to FDA development of ITM's product ITM-11 are required. These approvals and conditions are intended to occur more than three months after the date of shareholder approval obtained for the issue of the Consideration Shares. The Entity is entitled to hold back an amount of the consideration otherwise due to be paid at the completion of the Transaction as Consideration Shares to take account of final adjustments to the consideration and in relation to indemnity arrangements, with the potential for further Consideration Shares to be issued after completion of the Transaction as a consequence of those arrangements. Shareholders will know the maximum dilution to the Entity's capital structure at the time of voting on the resolution to approve the issue at the Entity's meeting and are able to provide their informed consent to the proposed issue. The extension of time requested by the Entity is made for clear and compelling commercial reasons such that the issue may occur outside the usual time constraints.
----------------------------------	---

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	7.3.4
Date	21/09/2026
ASX Code	TLX
Listed Company	TELIX PHARMACEUTICALS LIMITED
Waiver Number	WRR-0000533
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants Telix Pharmaceuticals Limited (the 'Entity'), a waiver from Listing Rule 7.3.4 in relation to its acquisition of ITM Isotope Technologies Munich SE ('ITM') (the 'Transaction'), to the extent necessary to permit the Entity in its notice of meeting ('Notice') seeking shareholder approval for the issue of up to US\$700 million worth of milestone shares ('Milestone Shares') to the vendors of ITM upon the achievement of milestones related to FDA development and sales targets of ITM's product ITM-11 ('Milestone Product'), not to state that the Milestone Shares will be issued within three months from the extraordinary general meeting ('EGM'), on the following conditions: 1.1 the Milestone Shares are to be issued upon achievement of the applicable milestones outlined below: 1.1.1 US\$100 million upon the FDA approving the next stage of development of the Milestone Product to occur no later than 31 March 2028; 1.1.2 US\$100 million upon the FDA approving the next stage of development of the Milestone Product to occur no later than 31 March 2031; 1.1.3 US\$50 million upon the FDA approving the next stage of the development of the Milestone Product to occur no later than 31 March 2032; and 1.1.4 Up to US\$450 million upon achievement of at least US\$150 million of global net sales of the Milestone Product in the calendar year ended 31 December 2030 to occur no later than 4 months after the issue of TLX's 2030 financial statements. 1.2 the material terms of Milestone Shares are fully and clearly set out in the Entity's Notice seeking shareholder approval in respect of the issue of the

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	Milestone Shares, including the relevant milestones for the issue of the Milestone Shares; 1.3 details regarding the potential dilutive effect of the Milestone Shares on the Entity's capital structure is included in the Notice to ASX's satisfaction; 1.4 the terms of the waiver are clearly disclosed in the Notice to ASX's satisfaction; 1.5 if any of the milestones are achieved, the achievement of that milestone and the basis on which the Entity's directors determined that the milestone has been achieved is announced to the market, along with the number of Milestone Shares issued; 1.6 for any annual reporting period during which any Milestone Shares have been issued or any of them remain to be issued, the Entity's annual report sets out the number of Milestone Shares issued in that annual reporting period, the number of Milestone Shares that remain to be issued and the basis on which the Milestone Shares may be issued; and 1.7 the Entity releases an announcement to the market that discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Entity that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.
Basis For Decision	Underlying Policy Listing Rule 7.3.4 requires a notice of meeting with a resolution to approve an issue or agreement to issue equity securities under Listing Rule 7.1 to include the date or dates on or by which the entity will issue the securities, which must be no later than the applicable period referred to in Listing Rule 7.3.4. This strikes a balance between giving entities the time practically necessary to complete an issue of equity securities, and ensuring that the securities are issued within a reasonable time frame after security holder approval so that the approval is not rendered stale by subsequent events. Present Application

	The Entity is proposing to seek shareholder approval to issue up to, in aggregate US\$700 million worth of Milestone Shares to the vendors as partial consideration for the Transaction. The issue of the Milestone Shares are tied to milestones relating to FDA regulatory development and a sales target of the Milestone Product. The specific timeframe for achievement of the milestones will be more than three months from the date of the EGM. Shareholders will know the maximum dilution to the Entity's capital structure at the time of voting on the resolution to approve the issue at the Entity's meeting and are able to provide their informed consent to the proposed issue of the Milestone Shares. The extension of time requested by the Entity is made for clear and compelling commercial reasons such that the issue may occur outside the usual time constraints.
--	---

Rule Number	6.23.2
Date	22/09/2026
ASX Code	AUC
Listed Company	AUSGOLD LIMITED
Waiver Number	WRR-0000536
Decision	1. Ausgold Limited (the 'Entity') is proposing to cancel for consideration unquoted warrants pursuant to a scheme of arrangement occurring under the Corporations Act. Based solely on the information provided, ASX Limited ('ASX') grants the Entity a waiver from Listing Rule 6.23.2 to the extent necessary to permit the cancellation of the warrants for consideration and without shareholder approval, on the following conditions: 1.1 Full details of the cancellation and the consideration payable are set out to ASX's satisfaction in the scheme booklet; and 1.2 The scheme of arrangement becomes effective. 2. This waiver is granted on the condition that the Entity releases an announcement to the market that discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Entity that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

Basis For Decision	Underlying Policy Standard waiver in accordance with Guidance Note 17. Present Application
---------------------------	--

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

Rule Number	10.1
Date	22/09/2026
ASX Code	KKC
Listed Company	KKR CREDIT INCOME FUND
Waiver Number	WRR-0000537
Decision	1. Subject to resolution 2, and based solely on the information provided, ASX Limited ('ASX') grants KKR Credit Income Fund (the 'Entity') a waiver from Listing Rule 10.1 to the extent necessary to permit the Entity to make initial and ongoing investments of the proceeds received from KKC's investment received from KKR Lending Partners Europe II (Euro) Unlevered SCSp ('EDL II') and KKR Lending Partners Europe III (Euro) SCSp ('EDL III') (collectively, the 'Funds'), as the Funds wind up, to invest in the successor fund to EDL III, KKR European Direct Lending (EEA) Feeder SCSp ('Evergreen EDL') and make redemptions of Evergreen EDL without unitholder approval. The waiver is granted on the following conditions: 1.1 funds are invested by KKR Australia Investment Management Pty Ltd, the manager of the Entity (the 'Manager'), in accordance with the investment objectives and strategy disclosed in the Entity's product disclosure statement dated 19 September 2019 (the 'PDS'); 1.2 redemptions and applications in the Evergreen EDL must occur in accordance with the representations made in the PDS; 1.3 applications for and redemptions of interests in Evergreen EDL occur on the basis of ordinary industry practices and prices that are consistent with what does or would apply to other investors in those funds; and 1.4 the Entity releases an announcement to the market that discloses the nature and effect of the waiver and the Entity's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Entity that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal or

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time. 2. Resolution 1 applies until 22 September 2029 and is subject to any amendments to the Listing Rules or changes in the interpretation and administration of the Listing Rules and policies of ASX.
Basis For Decision	Underlying Policy Listing Rule 10.1 requires an entity to obtain the approval of security holders for an acquisition or disposal of a substantial asset from or to a person in a position to exercise influence over the entity. This protects security holders from a value-shifting transaction between an entity and a person in a position to exercise influence over the entity without the disinterested security holders having approved that transaction with the benefit of full information. This supplements the related party provisions of the Corporations Act (or, in the case of a foreign entity, the related party provisions of the law of their home jurisdiction). Present Application The Entity's investment objective is to provide unitholders with an income stream as well as to achieve long-term capital appreciation, and it intends to continue to achieve this objective by investing proceeds from the Funds that are winding down and have a maximum investment period of three years from the Funds' final close. The final close of EDL II and EDL III occurred on 18 September 2020 and 2 March 2024, respectively. As such, the EDL III investment term will end by 1 March 2027 at which time EDL III will commence disposal of its assets and remittance of proceeds to limited partners, including the Entity. The

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	proceeds received from the Funds are proposed to be invested in a successor fund as a direct replacement of the Entity's investment in EDL III. The Manager is a related party of KKR Alternative Investment Management, the investment manager of Evergreen EDL as both the Manager and KKR Alternative Investment Management are under the common ownership of KKR Group Partnership L.P. Evergreen EDL is therefore considered to be a party to whom Listing Rule 10.1.5 applies. The value of the proceeds of investments received from the Funds as they wind down will exceed 5% of the equity interests in the Entity and accordingly will be considered a substantial asset for the purposes of Listing Rule 10.1. The PDS disclosed the nature of the Entity's structure and its investment objective and strategy and the manner in which it intends to achieve that strategy through the investment into a successor fund, and the fees payable to the parties. The investment in Evergreen EDL is considered to be a direct replacement of the Entity's investment in the Funds. A waiver from Listing Rule 10.1 is granted to permit the Entity to make initial and ongoing investments of proceeds from the Funds as they wind down, into Evergreen EDL and to make redemptions in Evergreen EDL.
--	--

Rule Number	6.23.3
Date	30/09/2026
ASX Code	SBM
Listed Company	ST BARBARA LIMITED
Waiver Number	WRR-0000538
Decision	1. Based solely on the information provided, ASX Limited ('ASX') grants St Barbara Limited (the 'Company') a waiver from Listing Rule 6.23.3 to the extent necessary to permit the Company to: • amend the exercise period applicable to 69,478,289 unquoted and unvested performance rights, retention rights and project incentive performance rights previously issued to employees and executives ('Affected Rights'), so that vested Affected Rights may be exercised during a period ending 15 years after their respective grant dates; and • introduce an entitlement to dividend equivalent payments in respect of vested but unexercised Affected Rights while the relevant participant remains employed by the Company or a group company, subject to the following conditions: 1.1 the Company obtains shareholder approval for the amendments pursuant to Listing Rule 6.23.4; and 1.2 the notice of meeting seeking shareholder approval includes explanatory information to the satisfaction of ASX pursuant to Listing Rule 6.23.4, including, at a minimum, a clear explanation of the rationale for the amendments, the operation of the deferred exercise arrangement and the dividend equivalent entitlement, so that shareholders can make an informed assessment. 2. This waiver is granted on the condition that the Company releases an announcement to the market that discloses the nature and effect of the waiver and the Company's reasons for seeking the waiver. The announcement must be released no later than the next business day after ASX communicates to the Company that the waiver has been granted, except when the waiver relates to a confidential and incomplete proposal

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED

	or negotiation. If the waiver relates to a confidential and incomplete proposal or negotiation, disclosure must be made when the matter ceases to be confidential or incomplete. ASX may direct the announcement to be made at another time.
Basis For Decision	Underlying Policy Listing Rule 6.23.3 requires that a change affecting an option cannot be made if it has the effect of reducing the exercise price, increasing the period for exercise or increasing the number of securities received on exercise. Changing these fundamental features affects the value of the option and a decision whether to buy, hold, sell, or exercise the option depends upon these features being known with certainty. These features also have the potential to affect the market in an entity's ordinary securities. Present Application The waiver from Listing Rule 6.23.3 permits the amendment of 69,478,289 unquoted and unvested performance rights, retention rights and project incentive performance rights previously issued under employee incentive arrangements for the purposes of adjusting certain aspects of the incentive structure in relation to vested Rights. The amendments would replace automatic exercise on vesting with a deferred exercise mechanism and introduce a dividend equivalent entitlement for vested but unexercised rights. Vesting conditions, performance hurdles and the number of shares received on exercise remain unchanged. The Affected Rights are unquoted remuneration securities, and the Company will seek shareholder approval under Listing Rule 6.23.4 before

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED



Register of ASX Listing Rule Waivers

	implementing the amendments.
--	------------------------------

ASX Limited ABN 98 008 624 691 and its related bodies corporate reserve all rights in the material incorporated in this publication. No part of this publication may be photocopied, reproduced, transcribed into or stored in a retrieval system or any other form of electronic medium, nor may it be transmitted in any form or by any means whether electronic, mechanical or otherwise without the prior written approval of the General Manager, Market Information, ASX Limited. NO RESPONSIBILITY IS ACCEPTED FOR ANY INACCURACIES IN THE MATTER PUBLISHED